Physician talking with a patient during a cardiology consultation

First in market in Europe

Willem 2.0 AI-ECG  for the early detection of cardiac diseases

Willem is now CE-marked to help physicians identify patients suggestive of heart failure and ATTR cardiac amyloidosis (ATTR-CM), alongside 29 cardiac patterns.

CE marked - Class IIa, EU-MDR, notified body 0051

What's new in Willem 2.0

One ECG. Far more answers.

From the same routine recording, Willem now helps identify patients suggestive of two cardiac diseases, alongside 29 cardiac patterns.

Two diseases that often go unnoticed, now detected by Willem 2.0

Some patients wait years for a diagnosis. From a standard 12-lead resting ECG, Willem detects AI-ECG digital biomarkers, signals the human eye can't see, to help shorten that wait.

Patient during a routine ECG check

Heart Failure

Spot it sooner, with reduced or preserved ejection fraction. Early symptoms are non-specific, so heart failure can stay undetected for years.

>50%

of cases may remain undetected1

64M+

People living with heart failure worldwide2

93%

of patients identified as Highly Suggestive are confirmed to have heart failure3

Download the Heart Failure one-pager

ATTR Cardiac Amyloidosis

Reach patients before years of misdiagnosis. Its symptoms mimic more common conditions., so patients often see several specialists before reaching a diagnosis.

34–57%

of patients initially misdiagnosed5

Up to 4 years

before a definitive diagnosis6

91%

of patients identified as Highly Suggestive are confirmed to have ATTR-CM3

Download the ATTR-CM one-pager

29 cardiac patterns
on any ECG device.

From a 10-second resting ECG to 14 days of continuous monitoring, one AI platform analyses every recording.

Resting 12-lead ECG
Holters and patches (1 and 2-lead)
Implantable cardiac monitors
Handheld devices

Atrial fibrillation / Flutter

AFib / Flutter
AFib / Flutter with Rapid Ventricular Response
AFib / Flutter with Controlled Ventricular Response
AFib / Flutter with Slow Ventricular Response

Tachycardia

Ventricular tachycardia
Supraventricular tachycardia

Ventricular Ectopy

PVC
PVC couplet
PVC triplet
PVC bigeminy
PVC trigeminy
PVC quadrigeminy

Atrial Ectopy

PAC
PAC couplet
PAC triplet
PAC bigeminy
PAC trigeminy
PAC quadrigeminy

Conduction and Pauses

Left bundle branch block
Right bundle branch block
1st-degree AV block
Pause

Sinus Rhythm

Sinus rhythm
Sinus tachycardia
Bradycardia
Sinus bradycardia
Mild sinus bradycardia
Moderate sinus bradycardia
Severe sinus bradycardia

Certified, secure and ready for clinical use

A Class IIa medical device under EU MDR, built on certified quality, security and data privacy frameworks.

Class IIa Medical Device

Certified under Regulation (EU) 2017/745 (EU MDR) for heart failure, ATTR cardiac amyloidosis and 29 cardiac patterns, for use by qualified healthcare professionals.

CE 0051

ISO Certified

Certified for information security, privacy, quality, AI management and anti-bribery.

ISO 27001
ISO 27017
ISO 27018
ISO 27701
ISO 37001
ISO 42001
IEC 81001

GDPR compliant

Meets the EU General Data Protection Regulation and the Spanish LOPD-GDD to ensure the lawful, secure processing of personal data.

Spanish National Security Scheme

ENS certified (High category) for multi-layered security and compliance with national cybersecurity regulations.

HDS

Certified for health data hosting in France, with all data hosted within the EEA.

DTAC*

Meets the NHS Digital Technology Assessment Criteria for quality, safety, interoperability and clinical effectiveness.

Peer-reviewed evidence

Published in Heart Rhythm

Dr. Pablo García-Pavía
Dr. Pablo García-Pavía
Clinical lead
Dr. Esther González-López
Dr. Esther González-López
First author
Hospital Universitario Puerta de Hierro Majadahonda

Improving Transthyretin cardiac amyloidosis detection from ECGs through Willem AI platform.

González-López E, et al. · Heart Rhythm · March 31, 2026
2,880 patients
517 ATTR-CM / 2,363 controls
0.88
AUC

Accuracy that makes every referral count

Validated in real-world clinical data, across different sites and populations

ATTR-CM

SpainUnited StatesNetherlandsGermany
3,797

patients across Europe and the US

91%

Highly Suggestive results confirmed as ATTR-CM

81%

Non-Suggestive results confirmed negative

Heart Failure

European UnionUnited States
69,905

patients across Europe and the US

93%

Highly Suggestive results confirmed as heart failure

9 in 10 patients9 in 10 patients

In both, 9 in 10 patients identified as Highly Suggestive were confirmed.

So the right patients reach confirmatory testing sooner.

Where Willem 2.0 makes a difference.

Wherever an ECG is recorded, Willem adds value: from primary care to cardiology and clinical research.

Physician reviewing a patient's results

Hospitals and clinicians

From primary care to cardiology

  • Support for routine ECG reads where cardiology isn’t on site
  • Triage of resting ECGs and long-term recordings (Holter, patches, ICMs), so the most relevant cases are reviewed first
  • Earlier, better-targeted referrals for Heart Failure and ATTR-CM
29 cardiac patterns
Heart failure
ATTR-CM

Technology partners

ECG devices, platforms and AI

  • Embedded in ECG devices (carts, Holters, patches, monitors), so every recording gets AI-ECG analysis
  • Available through clinical AI platforms, deployed within existing hospital workflows
  • Hardware agnostic and already CE-marked under EU-MDR for heart failure and ATTR-CM
29 cardiac patterns
Heart failure
ATTR-CM

Pharma and clinical research

Find and follow the right patients

  • Identify potentially eligible patients in existing ECG databases
  • Reach under-diagnosed populations, such as ATTR-CM and heart failure
  • Standardized, centralized ECG analysis across sites, countries and devices
29 cardiac patterns
Heart failure
ATTR-CM
Clinicians reviewing clinical data together

The data behind Willem

730,237

patients in Idoven's ECG database, behind every model Willem runs.

Built on real-world data, with clinicians.

100+

clinical partners worldwide

10+

years of cardiology expertise

35+

publications in high-impact journals

*INTENDED USE STATEMENT FROM THE WILLEM IFU": Willem interpretation results are not intended to be the sole means of diagnosis or replace traditional methods of treatment. It is offered on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. Please see Instructions of use for extended information about the product.

Contact

Revolutionize cardiovascular care with Idoven. Discuss the possibilities with us.
Thank you!
We will get back to you within 5 days, please check your spam folder
Back to Idoven
Oops! Something went wrong while submitting the form.
Thank you!
We will get back to you within 5 days, please check your spam folder
Back to Idoven
Oops! Something went wrong while submitting the form.

Download our Clinical Evidence